Fig. 1From: Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trialWaterfall plots of a BSR and b RECIST response of patients treated with cabozantinib at 100 mg a day and were included in this post hoc analysisBack to article page